Lancet Infectious Diseases

(The H4-Index of Lancet Infectious Diseases is 124. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-06-01 to 2024-06-01.)
Estimates of the severity of coronavirus disease 2019: a model-based analysis2666
Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective cohort study1259
Viral dynamics in mild and severe cases of COVID-191228
A minimal common outcome measure set for COVID-19 clinical research1136
A clinical case definition of post-COVID-19 condition by a Delphi consensus1062
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial1047
Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study939
Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics922
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial884
Clinical and virological data of the first cases of COVID-19 in Europe: a case series870
Global impact of the first year of COVID-19 vaccination: a mathematical modelling study868
Real estimates of mortality following COVID-19 infection855
Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study815
Clinical features and management of human monkeypox: a retrospective observational study in the UK745
Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study717
Scientific and ethical basis for social-distancing interventions against COVID-19646
Effectiveness of isolation, testing, contact tracing, and physical distancing on reducing transmission of SARS-CoV-2 in different settings: a mathematical modelling study641
Association between mobility patterns and COVID-19 transmission in the USA: a mathematical modelling study621
The value of antimicrobial peptides in the age of resistance619
Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study566
COVID-19 and multisystem inflammatory syndrome in children and adolescents564
Interventions to mitigate early spread of SARS-CoV-2 in Singapore: a modelling study563
Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance559
Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study554
Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study525
Genomic evidence for reinfection with SARS-CoV-2: a case study516
Evolving epidemiology and transmission dynamics of coronavirus disease 2019 outside Hubei province, China: a descriptive and modelling study473
Risk factors for SARS-CoV-2 among patients in the Oxford Royal College of General Practitioners Research and Surveillance Centre primary care network: a cross-sectional study460
What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2456
Vaccination and non-pharmaceutical interventions for COVID-19: a mathematical modelling study433
Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, mult430
COVID-19 and medical education414
A future vaccination campaign against COVID-19 at risk of vaccine hesitancy and politicisation411
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical 403
Stigma during the COVID-19 pandemic375
Investigation of a COVID-19 outbreak in Germany resulting from a single travel-associated primary case: a case series353
The temporal association of introducing and lifting non-pharmaceutical interventions with the time-varying reproduction number (R) of SARS-CoV-2: a modelling study across 131 countries348
Household secondary attack rate of COVID-19 and associated determinants in Guangzhou, China: a retrospective cohort study348
The many estimates of the COVID-19 case fatality rate341
Genomic characteristics and clinical effect of the emergent SARS-CoV-2 B.1.1.7 lineage in London, UK: a whole-genome sequencing and hospital-based cohort study340
Rapid implementation of SARS-CoV-2 sequencing to investigate cases of health-care associated COVID-19: a prospective genomic surveillance study335
Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 331
Risk of COVID-19 in health-care workers in Denmark: an observational cohort study329
Demographic and clinical characteristics of confirmed human monkeypox virus cases in individuals attending a sexual health centre in London, UK: an observational analysis313
Exaggerated risk of transmission of COVID-19 by fomites301
Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison301
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial300
The COVID-19 infodemic295
Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression285
Transmission of COVID-19 in 282 clusters in Catalonia, Spain: a cohort study284
Pooling of samples for testing for SARS-CoV-2 in asymptomatic people249
Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial249
Serology testing in the COVID-19 pandemic response247
Smell and taste dysfunction in patients with COVID-19242
Association of Plasmodium falciparum kelch13 R561H genotypes with delayed parasite clearance in Rwanda: an open-label, single-arm, multicentre, therapeutic efficacy study240
Long-term consequences of COVID-19: research needs238
Assessment of WHO antibiotic consumption and access targets in 76 countries, 2000–15: an analysis of pharmaceutical sales data237
Scaling up COVID-19 rapid antigen tests: promises and challenges236
SARS-CoV-2 infection and transmission in educational settings: a prospective, cross-sectional analysis of infection clusters and outbreaks in England235
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised231
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial228
Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-based observational study227
Hypoxaemia related to COVID-19: vascular and perfusion abnormalities on dual-energy CT225
Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial222
Changes in colistin resistance and mcr-1 abundance in Escherichia coli of animal and human origins following the ban of colistin-positive additives in China: an epidemiological comparative study216
Willingness to vaccinate against COVID-19 in Australia215
Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-cont211
Connecting clusters of COVID-19: an epidemiological and serological investigation207
Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical tri202
The global burden of HIV-associated cryptococcal infection in adults in 2020: a modelling analysis201
COVID-19 in health-care workers in three hospitals in the south of the Netherlands: a cross-sectional study200
COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study197
Intention to vaccinate against COVID-19 in Australia191
Monitoring approaches for health-care workers during the COVID-19 pandemic191
The global incidence and diagnosis of fungal keratitis191
Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: a retrospective, total population cohort study in Sweden189
The indirect impact of COVID-19 on women188
COVID-19 in children: the link in the transmission chain187
Post-acute effects of SARS-CoV-2 infection in individuals not requiring hospital admission: a Danish population-based cohort study187
Diagnostic performance of different sampling approaches for SARS-CoV-2 RT-PCR testing: a systematic review and meta-analysis185
Clinical characteristics of COVID-19 in 104 people with SARS-CoV-2 infection on the Diamond Princess cruise ship: a retrospective analysis183
Severity of omicron variant of concern and effectiveness of vaccine boosters against symptomatic disease in Scotland (EAVE II): a national cohort study with nested test-negative design181
Household transmission of SARS-CoV-2 and risk factors for susceptibility and infectivity in Wuhan: a retrospective observational study178
Molecular and clinical epidemiology of carbapenem-resistant Enterobacterales in the USA (CRACKLE-2): a prospective cohort study178
The important role of serology for COVID-19 control176
Intravesical bacteriophages for treating urinary tract infections in patients undergoing transurethral resection of the prostate: a randomised, placebo-controlled, double-blind clinical trial175
Likelihood of survival of coronavirus disease 2019174
Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial173
Global guideline for the diagnosis and management of rare mould infections: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and 172
What reinfections mean for COVID-19168
Global shortage of personal protective equipment166
ACE2 binding and antibody evasion in enhanced transmissibility of XBB.1.5166
SARS-CoV-2 seroprevalence and transmission risk factors among high-risk close contacts: a retrospective cohort study164
Real-world effectiveness of early molnupiravir or nirmatrelvir–ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wav162
Generation time of the alpha and delta SARS-CoV-2 variants: an epidemiological analysis162
Baricitinib for COVID-19: a suitable treatment?161
SARS-CoV-2 B.1.1.7 and B.1.351 spike variants bind human ACE2 with increased affinity160
Prevalence of mutations associated with resistance to macrolides and fluoroquinolones in Mycoplasma genitalium: a systematic review and meta-analysis159
Monkeypox virus isolation from a semen sample collected in the early phase of infection in a patient with prolonged seminal viral shedding158
SeroTracker: a global SARS-CoV-2 seroprevalence dashboard158
Utility of hyposmia and hypogeusia for the diagnosis of COVID-19156
Comparison of molecular testing strategies for COVID-19 control: a mathematical modelling study153
Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape151
Individual quarantine versus active monitoring of contacts for the mitigation of COVID-19: a modelling study151
Bell's palsy following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and nested case-control study151
Estimating the infection-fatality risk of SARS-CoV-2 in New York City during the spring 2020 pandemic wave: a model-based analysis145
Guidelines for pregnant women with suspected SARS-CoV-2 infection142
Indirect effects of the COVID-19 pandemic on malaria intervention coverage, morbidity, and mortality in Africa: a geospatial modelling analysis141
Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial141
Safety and efficacy of phage therapy in difficult-to-treat infections: a systematic review140
Neutralisation sensitivity of SARS-CoV-2 omicron subvariants to therapeutic monoclonal antibodies140
Risk of hospitalisation associated with infection with SARS-CoV-2 omicron variant versus delta variant in Denmark: an observational cohort study137
Clinical outcomes and bacterial characteristics of carbapenem-resistant Klebsiella pneumoniae complex among patients from different global regions (CRACKLE-2): a prospective, multicentre, cohort study135
Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial134
COVID-19 vaccine effectiveness against the omicron (BA.2) variant in England134
Monkeypox outbreaks outside endemic regions: scientific and social priorities133
Inappropriate empirical antibiotic therapy for bloodstream infections based on discordant in-vitro susceptibilities: a retrospective cohort analysis of prevalence, predictors, and mortality risk in US133
China's successful control of COVID-19132
Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial130
Prioritising COVID-19 vaccination in changing social and epidemiological landscapes: a mathematical modelling study130
Prevention of monkeypox with vaccines: a rapid review128
Monoclonal antibody therapies against SARS-CoV-2128
Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort study125
Bell's palsy and SARS-CoV-2 vaccines124
SARS-CoV-2 and the human-animal interface: outbreaks on mink farms124
Concerns and motivations about COVID-19 vaccination124